Lumos secures iMedical US$126k purchase order for FebriDx respiratory tests

Lumos Diagnostics has secured its largest purchase order for FebriDx respiratory tests to date with US$126k iMedical deal. 

Lumos’ FebriDx respiratory tests use a simple fingerstick blood test to achieve their results. Pic: Getty Images.

• iMedical order represents largest single purchase order since FebriDx launch

• FebriDx is a rapid point-of-care respiratory test which delivers results in about 10 minutes from a fingerstick blood sample

• Product is targeted at urgent or emergency care settings for evaluation of acute respiratory infections

Special Report: In a deal with Lumos Diagnostics, iMedical – a leading healthcare provider focused on providing cost-saving solutions – has purchased US$126,000 in FebriDx respiratory tests.

Lumos Diagnostics (ASX:LDX) says the deal represents its largest single purchase order to date, signalling an increase in US customer adoption and continued market acceptance of its point-of-care respiratory test.

iMedical is a leading developer and distributor of innovative cost-saving solutions for hospitals, surgery centres, clinics and healthcare facilities across the US.

FebriDx was cleared for sale in the US by the FDA in 2023, marketed as an aid in the diagnosis of bacterial acute respiratory infection and consequently as a method of ruling out bacterial causes of illness.

To be used in conjunction with clinical signs and symptoms, the test is designed for healthcare professionals with patients presenting in urgent or emergency care settings and is for the evaluation of patients for acute respiratory infections.

FebriDX tests. Image: Supplied

Rapid diagnostics vitally important

The ability to quickly and accurately identify the source of an illness in a clinical setting is invaluable to patient outcomes, enabling rapid and effective treatment before disease can advance further.

Independent clinical studies show the use of rapid diagnostic tests reduce mortality rates by more than 7%, improve antimicrobial stewardship outcomes to reduce the risk of developing antibiotic-resistant strains of bacteria, and decrease the length of hospital and intensive care stays.

The rapid tests market was valuedat US$1.46 billion in 2023, expected to grow at a compounding interest rate of 8.64%, to reach $3.08 billion by 2032.

Gaining traction and market acceptance

“We are excited to partner with Lumos Diagnostics to bring innovative diagnostic solutions to healthcare providers and patients,” said iMedical CEO Dave Berthold.

“This collaboration reflects our shared commitment to advancing point-of-care technology and improving health outcomes across the continuum of care."

Meanwhile Doug Ward, CEO and managing director of Lumos Diagnostics said that he is "pleased to see FebriDx gaining traction and acceptance in the market,” adding:

"It's a testament to the product’s clinical value and growing demand. Lumos looks forward to working more closely with iMedical to expand FebriDx’s market acceptance and adoption."

This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

Originally published as Lumos secures iMedical US$126k purchase order for FebriDx respiratory tests